Abstract Patients with haematological disorders have previously been considered to have poor outcomes following admission to intensive care units. Although a number of haematology centres from outside the UK have now demonstrated improved outcomes, the continuing
Introduction
Patients with haematological disorders requiring haematopoietic stem cell transplant (HSCT) or non-HSCT treatments have previously been considered to have poor outcomes following admission to intensive care units. Poor outcomes have particularly been associated with patients who have had HSCT (especially with myeloablative conditioning) [1] [2] [3] and patients who required mechanical ventilation [4] [5] [6] . Although a number of haematology centres from outside the UK have now demonstrated improved outcomes in patients requiring intensive care unit (ICU) support [7, 8] , the continuing perception of poor outcomes in this patient group may continue to adversely affect their chances of being admitted to some ICUs.
Over the past 10 years, there have been many advances within the disciplines of both haematology and intensive care medicine, which may improve patient outcomes, including those aimed at providing early identification of patients who are clinically deteriorating or at risk of deterioration using track-and-trigger systems (such as Early Warning Scores (EWS)), and earlier involvement of ICU staff, for example using critical care outreach teams. A recent review of outcomes of a large number of haematology patients requiring ICU in UK is relatively lacking especially after all these advances in ICU care.
We have undertaken a retrospective analysis of haematology patients who required admission to an ICU or high dependency unit (HDU) facility within a UK teaching hospital with a large department of clinical haematology and stem cell transplantation. Data has been analysed before and after the introduction of an EWS system, critical outreach nursing and continuous consultant intensive care physician cover for HDU patients, in order to assess the impact of these changes on patient outcomes in terms of escalation of therapy and survival.
Methods
A retrospective analysis was performed of 105 patients with haematological malignancies (HSCT or non-HSCT) admitted to the ICU at Nottingham University Hospital (City Campus) between April 2006 to August 2008. The ICU is a 16-bed mixed-dependency ICU caring for both levels 2 (HDU) and 3 (ICU) patients and staffed by consultant intensive care physicians, sharing responsibility of care with the admitting physicians. Prior to 2005, the hospital operated separate HDU and ICUs with HDU patients cared for by their home teams. There has been no expansion in absolute numbers of critical care beds during the period of the study. In 2005, an EWS system with outreach-team involvement was extended to haematology wards in order to identify patients at risk of deterioration. Using the EWS protocol, patients identified as reaching a preset trigger led to a review by an outreach team consisting of specialist ICU nurses to assess whether ICU admission was required or whether further support could be provided within the ward environment. Patients continued to be monitored by the outreach team until their EWS score had either fallen to below the preset trigger or they were transferred to the ICU. Standard EWS cutoffs were applied to all patients.
The protocol using EWS and outreach teams (Table 1) in haematology wards was applied to all inpatients. EWS score was based on pulse, blood pressure, respiratory rate, temperature, central nervous system function and urine output recorded every 6 h. For each parameter, an abnormal observation would score 0 to 3 depending upon the degree of abnormally high or low reading. All the points were added to give a total EWS score. If this score was <3, observations were continued every 6 hourly. If the score was 3, hourly observations and EWS scoring were done. If the score remained at 3 for 4 h, medic on the ward was informed to review the patient and to institute appropriate management. If the EWS reached 4 or more, ICU outreach team was informed to review the patient in addition to the medic on the ward. Outreach team would then monitor patient hourly and also set up high flow oxygen, if needed, until EWS score is back down to less than 4 with treatment or, otherwise, inform the ICU physicians, if EWS continued to deteriorate, for transfer of patient to ICU after their review. The purpose was neither to transfer patients too late when they were already extremely unwell nor too early when they could be managed on the wards with close liaison with ICU outreach team.
Data 9 / l and moderate to severe liver failure if bilirubin or liver enzymes were greater than twice of upper normal limit.
In addition, the requirement of patients for specific levels of intervention was recorded, where level 2 support is that required for single organ failure; for example, inotropes or non-invasive ventilation; and level 3 support is defined as the support of multiple organs, or endotracheal intubation and mechanical ventilation alone (typically HDU care is considered level 2 and ICU level 3).
ICU survival and survival to discharge from hospital were recorded as was survival and disease status at 6 months. For HSCT patients, type of transplant (related or unrelated), intensity of conditioning (myeloablative or non-myeloablative), days post-transplantation at the time of ICU admission, presence or absence of graft-versus-host disease and steroid use were also recorded.
Data was analysed to assess proportion of patients discharged from ICU and from the hospital, proportion of patients alive at 6 months and their disease status (CR, PR, disease relapse/progression) and overall survival. Overall survival was calculated from ICU admission until death or censor at date of analysis. Univariate and multivariate analysis of variables for overall survival was done using Graphpad Prism and SPSS.
Similar data was collected and analysed for haematology patients admitted to ICU in 2004, which provided us with a pre-EWS group of patients for comparison.
Results
The patient characteristics are shown in Table 2 transplant patients were post-autologous HSC transplant, and 30 were post-allogeneic transplant. Out of the 30 allogeneic transplant recipients, 16 had non-myeloablative, and 14 had myeloablative conditioning. Most of the patients had received peripheral blood stem cells. Between 30% and 40% of patients in both groups were suffering from graft versus host disease and were on immunosuppressants and steroids.
The main reasons for requiring critical care support were respiratory failure secondary to chest infection, or sepsis. Other causes are listed in Table 3 . The length of ICU stay varied from 0.01 to 34 days. The organs which were affected at the time of admission in 2006-2008 group of patients are shown in Table 3 . The most frequent was respiratory failure (84%) followed by haematological failure (neutropenia with neutrophils <1.0×10 9 /l; 48%), moderate to severe renal failure (28%), moderate to severe liver impairment (32%), gastroenterological dysfunction (24%), cardiac failure (13%) and neurological dysfunction (14%). The percentages of different organs affected were quite similar in 2004 group, with the exception of gastroenterological dysfunction (7%) and cardiac failure (1%) which were seen lesser. The number of patients considered to have more than two organ failures was 44% Table 4 . The median length of stay for all patients increased from 3 to 4 days, although that of level 3 patients remained relatively static throughout the time period of the study at 5 days. There was an increase in the proportion of all patients surviving to discharge from hospital, and this also was reflected in level 3 patients, including those who underwent mechanical ventilation. Only two patients who required renal replacement therapy survived to be discharged from hospital. Longer term survival at 3 and 6 months also appeared to be improved, though the trend became more modest. The median follow-up of patients who survived ICU admission and were discharged from hospital was 9 months.
A small number of patients in both groups were discharged from ICU to receive palliative care on the haematology wards.
The disease status of survivors at 6 months revealed that, in 2006-2008, 91% were in complete remission from their respective haematological conditions, and a further 6% were in partial remission. Only a small minority of 3% had already relapsed by 6 months. These results were similar to that seen in 2004 with only one patient in each group suffering a relapse. The overall survival at 1 year of the whole cohort of patients admitted to ICU during 2006-2008 was 31% (Fig. 1) .
Proportionally, more HSCT patients survived to hospital discharge and were alive at 6 months in 2006-2008. One year overall survival of HSCT patients was 36% (Fig. 1) . Of these patients, 93% were in remission at 6 months. All of the HSCT patients who were alive at 6 months were also in complete remission. The only patient who relapsed also went back to complete remission after receiving donor lymphocyte infusion. HSCT patients appeared to have equally good outcomes when compared to non-HSCT patients in [2006] [2007] [2008] analysis, only failure of greater than two organs proved to be an independently significant factor adversely affecting survival (p value 0.002; Table 5 ).
Discussion
There have been more recent reports (2008, 2009) on outcomes of haematology patients to ICU showing improvement consistently in most. However, the indications and timing of ICU admissions is still not entirely clear. Our study suggests an improvement in outcomes following the development of an early warning system allowing for early recognition of patients at risk of deterioration, early involvement of critical care outreach teams and subsequent transfer to ICU/HDU if needed. During the time period involved, critical care was also restructured allowing for greater collaboration between intensive care physicians and haematologists. The increase in both overall ICU admissions and patients requiring level 3 support over the time period, coupled with the trend towards decreasing average APACHE scores, suggests that appropriate patients are being identified earlier and are having their treatment escalated accordingly. During the same time period, the involvement of ICU outreach team allowed for patients to receive far higher concentrations of "high-flow" humidified oxygen and aggressive fluid resuscitation and intermittent central venous monitoring whilst remaining on the haematology wards.
Previous studies have suggested that as many as 7% of haematology admissions for malignancy are complicated by critical illness, and 1.7% are admitted to intensive care [9] . The total number of haematology admissions to hospital during the time period (2006) (2007) (2008) are not known, so it is possible that the absolute increase in level 3 ICU admissions reflects an absolute increase in hospital admissions, and that the use of critical care outreach teams masks the increase in level 2 requirement. The study confirmed the findings of other studies that good outcomes in terms of short-term and medium-term survival are possible in this cohort of patients with 53% of patients discharged from ICU back to the ward, and in 33% of patients being alive at 6 months, out of which, majority (91%) were in complete remission from their respective haematological conditions [10] [11] [12] . We also looked at the outcomes of all non-surgical patients admitted to ICU as well as hospital mortality for comparison with patients with haematological malignancies. The ICU mortality of all non-surgical patients in 2007 was 26.9%, and hospital mortality was 37.4%. Hence, although the ICU survival of haematology patients admitted to ICU was lower as compared to other non-surgical admissions, still the results were not too far off. In 2006-2008, haematology patients requiring ICU admission had a 1-year survival of 31%. Patients who were admitted to ICU after HSCT had an equally good outcome with 1-year survival of 36%. This is contrary to what has been reported previously in a number of studies in which HSCT patients had done worse as compared to non-HSCT patients [3] and confirms no difference in outcome shown in other more recently published studies [13] [14] [15] . Reduced intensity conditioning, better (high resolution) HLA tissue typing, close monitoring of cytomegalovirus (CMV) with real time quantitative PCR with treatment of CMV reactivation to prevent CMV disease and improvement in anti-bacterial and anti-fungal treatments are some factors, to mention the least, which may have improved outcomes of HSCT patients. Amongst the 39 ICU admissions of HSCT patients, there was no significant difference in outcomes of myeloablative versus non-myeloablative conditioning transplant recipients. This again is contrary to previous reports of myeloablative transplant recipients doing worse as compared to nonmyeloablative conditioning.
Patients requiring mechanical ventilation did slightly worse than those not requiring mechanical ventilation, but this difference in outcome did not prove to be statistically significant on univariate as well as multivariate analysis. This is reflected in the increasing proportion of patients surviving after mechanical ventilation and conflicts with previous studies which indicate mechanical ventilation to be a marker of poor outcome [12, [16] [17] [18] [19] . Failure of greater than two organs, neutropenia, renal support and inotropic support were significant factors on univariate analysis, but on multivariate analysis, only failure of greater than two organs proved to be an independently significant factor adversely affecting survival. Unfortunately, one of the limitations of this study is the relatively low sample size making multivariate analysis less reliable; however, it is reasonable to assume that late transfer to ICU once patients have already developed multiple organ failure is likely to be associated with poorer outcomes. Although this study is limited by being retrospective in nature, and of a heterogenous population, it suggests firstly that the outcomes of haematology patients admitted to ICU have improved and that the threshold for admission and also for instituting level 3 care decreased. This trend towards improved outcomes is also present amongst haematopoietic stem cell transplant patients. Secondly, it also suggests that the earlier involvement of critical care using EWS scoring, critical care outreach and earlier involvement of intensive care physicians has played a role in any improvement. Thirdly, in addition to the improved outcomes of patients with haematological malignancies admitted to ICU, a vast majority of these patients who survive ICU admission are in complete remission, especially the ones after HSCT, and many cured of their underlying malignancies. Hence, reluctance to admit these patients receiving intensive and potentially curative treatments to ICU on the basis of their underlying haematological malignancy is not justified.
We suggest that the recent National Institute of Clinical Excellence (NICE, UK) guidelines advocating the use of EWS or a similar trigger system for all adult hospital patients at risk of deterioration are likely to benefit hospitals involved in intensive treatments such as those required for haematology patients [20, 21] .
